Humacyte, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
HUMA Nasdaq 3850 humacyte.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Humacyte, Inc.

Humacyte, Inc. (NASDAQ:HUMA): Are Analysts Optimistic? - Jan 13th, 2026 3:32 am
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications - Jan 8th, 2026 6:00 am
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Jan 7th, 2026 7:40 am
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - Jan 5th, 2026 6:00 am
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair - Dec 22nd, 2025 6:00 am
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital - Dec 16th, 2025 6:00 am
Humacyte (HUMA): Benchmark Remains Bullish on Stock - Dec 10th, 2025 12:12 pm
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest? - Dec 5th, 2025 7:30 am
Humacyte, Inc.'s (NASDAQ:HUMA) largest shareholders are retail investors with 57% ownership, institutions own 26% - Dec 3rd, 2025 3:29 am
Humacyte (HUMA) Q3 2025 Earnings Call Transcript - Nov 27th, 2025 4:16 pm
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results - Nov 20th, 2025 6:00 am
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) - Nov 13th, 2025 6:00 am
Why Humacyte (HUMA) Is Rising After Positive Phase 3 Results in High-Risk Hemodialysis Patients - Nov 12th, 2025 3:17 pm
Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ... - Nov 12th, 2025 12:03 pm
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates - Nov 12th, 2025 6:30 am
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update - Nov 12th, 2025 5:00 am
Humacyte (HUMA): Evaluating Valuation Following Promising Phase 3 V007 Results in Hemodialysis Access - Nov 11th, 2025 2:11 am
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025 - Nov 10th, 2025 6:00 am
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors - Nov 6th, 2025 4:00 pm
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025 - Nov 6th, 2025 6:00 am